Stockreport

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF oxaliplatin (GemOx), for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of overall survival. Columvi is R [Read more]